merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Lilly is positioning its vials as a safer, FDA-approved option that is controlled for safety, quality, and effectiveness, unlike compounded drugs which are subject to far less oversight.</answer>
<question_number>2</question_number>
<answer>By offering Zepbound vials through its own telehealth platform, LillyDirect, and delivering them directly to patients' doors, Eli Lilly is directly replicating and competing with the business model of telehealth companies that prescribe and deliver compounded medications.</answer>
<question_number>3</question_number>
<answer>The implicit risk is that compounded drugs are subject to far less oversight and are not controlled for safety, quality, and effectiveness.</answer>
<question_number>4</question_number>
<answer>It is seen as a strategic move to regain customers and market share from the telehealth companies and compounding pharmacies offering cheaper alternatives.</answer>
<question_number>5</question_number>
<answer>Compounding pharmacies can legally make copycat versions of any medication that the Food and Drug Administration lists as "in shortage." Once tirzepatide is removed from the shortage list, the legal basis for compounding it will be gone, strengthening Lilly's legal challenges.</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>Older patients on Medicare, who are not covered for weight-loss drugs, may be attracted to the lower-cost vials and face unique risks such as loss of muscle mass, which can lead to fractures or frailty.</answer>
<question_number>8</question_number>
<answer>By positioning its vials as a safer, FDA-approved option and highlighting the lack of safety and quality control for compounded drugs, the article implies that patients may begin to perceive the compounded versions as less safe.</answer>
<question_number>9</question_number>
<answer>Its listing on the Food and Drug Administration's "in shortage" list.</answer>
<question_number>10</question_number>
<answer>Lowering the price of its own product to signal to the compounding market that it will fight to regain market share.</answer>